<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Malar J</journal-id><journal-id journal-id-type="iso-abbrev">Malar. J</journal-id><journal-title-group><journal-title>Malaria Journal</journal-title></journal-title-group><issn pub-type="epub">1475-2875</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23680454</article-id><article-id pub-id-type="pmc">3662604</article-id><article-id pub-id-type="publisher-id">1475-2875-12-163</article-id><article-id pub-id-type="doi">10.1186/1475-2875-12-163</article-id><article-categories><subj-group subj-group-type="heading"><subject>Commentary</subject></subj-group></article-categories><title-group><article-title>Fulani show decreased susceptibility to <italic>Plasmodium falciparum</italic> infection <italic>versus</italic> Mossi: data from a community-wide screening and treatment of asymptomatic carriers in Burkina Faso</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Tiono</surname><given-names>Alfred B</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>t.alfred@fasonet.bf</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Sirima</surname><given-names>Sodiomon B</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>s.sirima.cnlp@fasonet.bf</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Hamed</surname><given-names>Kamal</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>kamal.hamed@novartis.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Centre National de Recherche et de Formation sur le Paludisme, Minist&#x000e8;re de la Sant&#x000e9;, 01 BP 2208, Ouagadougou, Burkina Faso</aff><aff id="I2"><label>2</label>Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936-1080, USA</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>16</day><month>5</month><year>2013</year></pub-date><volume>12</volume><fpage>163</fpage><lpage>163</lpage><history><date date-type="received"><day>23</day><month>1</month><year>2013</year></date><date date-type="accepted"><day>14</day><month>5</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Tiono et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Tiono et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.malariajournal.com/content/12/1/163"/><abstract><sec><title>Background</title><p>The Fulani ethnic group is known to have a lower susceptibility to <italic>Plasmodium falciparum</italic> infection than the Mossi.</p></sec><sec><title>Methods</title><p>This commentary describes data from a recent cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of <italic>P. falciparum</italic> in 18 villages in Sapon&#x000e9;, Burkina Faso.</p></sec><sec><title>Results</title><p>The Fulani groups had a lower proportion of asymptomatic carriers at any occasion, a lower density of asexual forms and gametocytes of <italic>P. falciparum</italic> at baseline, and, in children under five years of age, lower rates of symptomatic malaria episodes per person-year than the Mossi.</p></sec><sec><title>Discussion and conclusion</title><p>These data confirm previously reported differences in <italic>P. falciparum</italic> susceptibility between Fulani and Mossi.</p></sec></abstract><kwd-group><kwd>Malaria</kwd><kwd><italic>Plasmodium falciparum</italic></kwd><kwd>Mossi</kwd><kwd>Fulani</kwd><kwd>Artemether-lumefantrine</kwd></kwd-group></article-meta></front><body><sec><title>Background and methods</title><p>Recent investigations into the ethnic susceptibility of Fulani and Mossi for <italic>Plasmodium falciparium</italic> infection have consistently reported that Fulani have a lower susceptibility than Mossi [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. A recent cluster-randomized trial in 18 villages in Sapon&#x000e9;, Burkina Faso, which investigated the systematic, community-wide screening and treatment of asymptomatic carriers of <italic>P. falciparum</italic> with artemether-lumefantrine (AL) [<xref ref-type="bibr" rid="B6">6</xref>], provided further data on the susceptibility differences between these two ethnic groups. This trial enrolled a combined majority of Fulani and Mossi subjects and assessed the incidence of microscopy-confirmed asymptomatic carriage, asexual forms and gametocytes, as well as &#x02018;symptomatic malaria episodes including fever and a parasite density &#x0003e;5,000/&#x003bc;l&#x02019; (abbreviated as SMRC5000 throughout the text) at various time points over the 12-month study [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>While the exact biological reason for the lower susceptibility to <italic>P. falciparum</italic> of Fulani compared with Mossi is not fully understood, it is known that it is not due to an increased frequency of classic malaria-resistance genes, such as haemoglobin S, haemoglobin C, -alpha 3.7 deletional thalassaemia, G6PDA-, and HLA B*5301 [<xref ref-type="bibr" rid="B7">7</xref>]. However, Fulani have been shown to have higher levels of antibodies against two <italic>P. falciparum</italic> antigens [<xref ref-type="bibr" rid="B3">3</xref>] and stronger malaria-specific IgG, IgG1, IgG3 and IgM responses [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>Further investigations into immunological differences that may affect susceptibility to <italic>P. falciparum</italic> have centred on Fc&#x003b3;RIIa genotypes that affect the binding of different IgG subclasses. The Fc&#x003b3;RIIa-H/H131 genotype is associated with higher levels of anti-malarial IgG2 and IgG3 antibodies, while the Fc&#x003b3;RIIa-R/R131 genotype is associated with higher levels of IgG1 antibodies [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. Individuals with the R allele of Fc&#x003b3;RIIa have higher antibody levels than those with the H allele [<xref ref-type="bibr" rid="B11">11</xref>]. The Fc&#x003b3;RIIa-H/H131 genotype and H131 allele are reported to exist at higher frequencies in the Fulani ethnic group [<xref ref-type="bibr" rid="B10">10</xref>]. However, there is a similar distribution of Fc&#x003b3;RIIa-R131H polymorphism in Fulani and Mossi [<xref ref-type="bibr" rid="B11">11</xref>]. Overall, Fulani have higher antibody levels than Mossi [<xref ref-type="bibr" rid="B11">11</xref>]. Additionally, in Fulani, it is known that the IL4-524&#x000a0;T allele, which codes for the Th2 cytokine interleukin-4, is at high frequency and is associated with elevated antibody levels against malarial antigens [<xref ref-type="bibr" rid="B12">12</xref>]. A functional deficit of T regulatory cells may also contribute to Fulani having a higher resistance to malaria [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>It has also been demonstrated that parasitaemia in asymptomatic Fulani is more common in individuals with lactase non-persistence genotypes (lactose intolerance), although this difference was not statistically significant [<xref ref-type="bibr" rid="B5">5</xref>]. This suggests that the potential immunoprotective properties of dietary cow&#x02019;s milk may contribute to the partial malaria resistance of Fulani, yet this requires further investigation [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>This commentary describes differences in susceptibility to <italic>P. falciparum</italic> infection between Fulani and Mossi subjects in the above-mentioned study [<xref ref-type="bibr" rid="B6">6</xref>].</p><sec><title>Ethics section</title><p>The protocol and the informed consent form were reviewed and approved by the Institutional Review Board of the Centre National de Recherche et de Formation sur le Paludisme and by the National Ethical Committee for Health Research of Burkina Faso. Prior to study initiation, a community meeting was held in each of the selected clusters to discuss the study with the community. The freedom of each individual household and a household member to decide on participation was discussed to minimize the potential influence of key opinion leaders in each cluster. Individual informed consent was obtained from each participant during a visit to the household before any study procedure.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Baseline characteristics</title><p>In total, 14,075 subjects aged between one month and 104&#x000a0;years were enrolled. The intervention arm included 6,817 subjects with a mean age of 24.1&#x000a0;years, of whom 46.4% were male, 90.6% were Mossi and 8.7% were Fulani. The control arm included 7,258 subjects with a mean age of 23.4&#x000a0;years, of whom 47.4% were male, 95.7% were Mossi and 3.8% were Fulani. The intervention and control arms had similar proportions of children less than five years of age (17.0% and 15.6%, respectively).</p></sec><sec><title><italic>Plasmodium falciparum</italic> infection rates by ethnicity</title><sec><title>Proportions of asymptomatic carriers</title><p>The Fulani groups had a lower proportion of microscopy-confirmed asymptomatic carriers than the Mossi groups at any occasion (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>). Subjects may have been counted multiple times if diagnosed as asymptomatic carriers more than once during the study.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold><italic>P. falciparum </italic></bold><bold>microscopy-confirmed asymptomatic carriers at any occasion.</bold></p></caption><graphic xlink:href="1475-2875-12-163-1"/></fig></sec></sec><sec><title>Parasite densities (asexual forms and gametocytes)</title><p>The Fulani groups had lower densities of microscopy-confirmed <italic>P. falciparum</italic> asexual forms (Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref>) and gametocytes (Figure&#x000a0;<xref ref-type="fig" rid="F3">3</xref>) than the Mossi groups at baseline.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Density of </bold><bold><italic>P. falciparum </italic></bold><bold>asexual forms by microscopy at baseline.</bold></p></caption><graphic xlink:href="1475-2875-12-163-2"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Density of </bold><bold><italic>P. falciparum </italic></bold><bold>gametocytes by microscopy at baseline.</bold></p></caption><graphic xlink:href="1475-2875-12-163-3"/></fig></sec><sec><title>Incidence of SMRC5000</title><p>In children under five years of age, the Fulani groups had lower rates of SMRC5000 per person-year than the Mossi groups at follow-up (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>). However, when the analysis included subjects of all ages, the Fulani groups had higher rates of SMRC5000 per person-year than the Mossi groups (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p><bold>SMRC5000* per person-year in infants and children (under five years) at follow</bold>-<bold>up (all subjects diagnosed at any time with asymptomatic carriage)</bold></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left"><bold>Study arm</bold></th><th align="left"><bold>Ethnicity</bold></th><th align="left"><bold>Number of SMRC5000</bold></th><th align="left"><bold>Person-year observed</bold></th><th align="left"><bold>SMRC5000 per person-year</bold></th></tr></thead><tbody valign="top"><tr><td rowspan="2" align="left" valign="top"><bold>Intervention (n&#x02009;=&#x02009;512)</bold><hr/></td><td align="left" valign="bottom">Mossi<hr/></td><td align="left" valign="bottom">384<hr/></td><td align="left" valign="bottom">350.6<hr/></td><td align="left" valign="bottom">1.10<hr/></td></tr><tr><td align="left" valign="bottom">Fulani<hr/></td><td align="left" valign="bottom">31<hr/></td><td align="left" valign="bottom">32.8<hr/></td><td align="left" valign="bottom">0.95<hr/></td></tr><tr><td rowspan="2" align="left" valign="top"><bold>Control (n&#x02009;=&#x02009;203)</bold></td><td align="left" valign="bottom">Mossi<hr/></td><td align="left" valign="bottom">154<hr/></td><td align="left" valign="bottom">149.1<hr/></td><td align="left" valign="bottom">1.03<hr/></td></tr><tr><td align="left">Fulani</td><td align="left">7</td><td align="left">9.3</td><td align="left">0.76</td></tr></tbody></table><table-wrap-foot><p>* SMRC5000&#x02009;=&#x02009;Symptomatic malaria episodes including fever and a parasite density &#x0003e;5,000/&#x003bc;l.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p><bold>SMRC5000* per person-year in subjects of all ages at follow</bold>-<bold>up (all subjects diagnosed at any time with asymptomatic carriage)</bold></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left"><bold>Study arm</bold></th><th align="left"><bold>Ethnicity</bold></th><th align="left"><bold>Number of SMRC5000</bold></th><th align="left"><bold>Person-year observed</bold></th><th align="left"><bold>SMRC5000 per person-year</bold></th></tr></thead><tbody valign="top"><tr><td rowspan="2" align="left" valign="top"><bold>Intervention (n&#x02009;=&#x02009;2,740)</bold><hr/></td><td align="left" valign="bottom">Mossi<hr/></td><td align="left" valign="bottom">722<hr/></td><td align="left" valign="bottom">1928.1<hr/></td><td align="left" valign="bottom">0.37<hr/></td></tr><tr><td align="left" valign="bottom">Fulani<hr/></td><td align="left" valign="bottom">57<hr/></td><td align="left" valign="bottom">116.8<hr/></td><td align="left" valign="bottom">0.49<hr/></td></tr><tr><td rowspan="2" align="left" valign="top"><bold>Control (n&#x02009;=&#x02009;1,381)</bold></td><td align="left" valign="bottom">Mossi<hr/></td><td align="left" valign="bottom">257<hr/></td><td align="left" valign="bottom">1024.2<hr/></td><td align="left" valign="bottom">0.25<hr/></td></tr><tr><td align="left">Fulani</td><td align="left">14</td><td align="left">29.2</td><td align="left">0.48</td></tr></tbody></table><table-wrap-foot><p>* SMRC5000&#x02009;=&#x02009;Symptomatic malaria episodes including fever and a parasite density &#x0003e;5,000/&#x003bc;l.</p></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Demographic surveillance data for the district show the distribution of Fulani and Mossi in the area as 7.1% and 90.7%, respectively. The proportions of each group enrolled in the study are generally consistent with this (8.7% and 90.6% in the intervention arm, 3.8% and 95.7% in the control arm).</p><p>The data we present confirm previously reported differences in susceptibility to <italic>P. falciparum</italic> malaria between Fulani and Mossi ethnic groups [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. There was a consistently reduced incidence of the indicators for <italic>P. falciparum</italic> infection in Fulani over Mossi (Figures&#x000a0;<xref ref-type="fig" rid="F1">1</xref>, <xref ref-type="fig" rid="F2">2</xref> and <xref ref-type="fig" rid="F3">3</xref> and Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>), except for a reversal of this trend in the rates of SMRC5000 per person-year in subjects of all ages at follow-up (all subjects diagnosed at any time for asymptomatic carriage, Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>).</p><p>This inconsistency in SMRC5000 per person-year in infants and children (under five years) and in subjects of all ages at follow-up (Tables&#x000a0;<xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>) was unanticipated. One possible reason for this may be that treatment of asymptomatic carriers with artemisinin-based therapy may increase subsequent susceptibility to symptomatic malaria more in adult Fulani who are known to have stronger immune responses to malaria than in Mossi.</p><p>Therefore, areas for further research include a more detailed assessment of differences in SMRC5000 (per person-year) between children and adults and any biological reasons for these differences, as well as investigations into potential interethnic differences in the effect of artemisinin derivatives on naturally acquired protective immunity. Other beneficial studies may assess intra-Fulani susceptibility distribution, which may correlate with previously reported differences in anti-malarial antibody levels amongst the Fulani themselves [<xref ref-type="bibr" rid="B12">12</xref>].</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Data from the systematic, community-wide screening and treatment of asymptomatic carriers of <italic>P. falciparum</italic> with artemether-lumefantrine (AL) [<xref ref-type="bibr" rid="B6">6</xref>] confirm previously reported differences in <italic>P. falciparum</italic> susceptibility between Fulani and Mossi.</p></sec><sec><title>Abbreviations</title><p>SMRC5000: Symptomatic malaria episodes including fever and a parasite density &#x0003e;5,000/&#x003bc;l.</p></sec><sec><title>Competing interests</title><p>AT has received honoraria from Novartis Pharma AG, Basel, Switzerland to attend Advisory Board meetings to discuss this study. KH is an employee of Novartis Pharmaceuticals Corporation. SS has declared no competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>All authors were involved in the design of the primary study and defining the content for, writing and critically reviewing this manuscript. AT and SS were involved in data collection, while AT and KH conducted the data analysis. All authors had full access to data in the study, discussed the results, reviewed the draft manuscript and agreed on the final version. AT had final responsibility for the decision to submit the manuscript for publication. Editorial assistance was provided by PreScript Communications, with funding from Novartis Pharma AG.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Modiano</surname><given-names>D</given-names></name><name><surname>Petrarca</surname><given-names>V</given-names></name><name><surname>Sirima</surname><given-names>BS</given-names></name><name><surname>Bosman</surname><given-names>A</given-names></name><name><surname>Nebie</surname><given-names>I</given-names></name><name><surname>Diallo</surname><given-names>D</given-names></name><name><surname>Lamizana</surname><given-names>L</given-names></name><name><surname>Esposito</surname><given-names>F</given-names></name><name><surname>Coluzzi</surname><given-names>M</given-names></name><article-title><italic>Plasmodium falciparum</italic> malaria in sympatric ethnic groups of Burkina Faso, west Africa</article-title><source>Parassitologia</source><year>1995</year><volume>37</volume><fpage>255</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">8778668</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Modiano</surname><given-names>D</given-names></name><name><surname>Petrarca</surname><given-names>V</given-names></name><name><surname>Sirima</surname><given-names>BS</given-names></name><name><surname>Nebie</surname><given-names>I</given-names></name><name><surname>Diallo</surname><given-names>D</given-names></name><name><surname>Esposito</surname><given-names>F</given-names></name><name><surname>Coluzzi</surname><given-names>M</given-names></name><article-title>Different response to <italic>Plasmodium falciparum</italic> malaria in west African sympatric ethnic groups</article-title><source>Proc Natl Acad Sci USA</source><year>1996</year><volume>93</volume><fpage>13206</fpage><lpage>13211</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.23.13206</pub-id><pub-id pub-id-type="pmid">8917569</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Modiano</surname><given-names>D</given-names></name><name><surname>Chiucchiuini</surname><given-names>A</given-names></name><name><surname>Petrarca</surname><given-names>V</given-names></name><name><surname>Sirima</surname><given-names>BS</given-names></name><name><surname>Luoni</surname><given-names>G</given-names></name><name><surname>Perlmann</surname><given-names>H</given-names></name><name><surname>Esposito</surname><given-names>F</given-names></name><name><surname>Coluzzi</surname><given-names>M</given-names></name><article-title>Humoral response to <italic>Plasmodium falciparum</italic> Pf155/ring-infected erythrocyte surface antigen and Pf332 in three sympatric ethnic groups of Burkina Faso</article-title><source>AmJTrop Med Hyg</source><year>1998</year><volume>58</volume><fpage>220</fpage><lpage>224</lpage></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Torcia</surname><given-names>MG</given-names></name><name><surname>Santarlasci</surname><given-names>V</given-names></name><name><surname>Cosmi</surname><given-names>L</given-names></name><name><surname>Clemente</surname><given-names>A</given-names></name><name><surname>Maggi</surname><given-names>L</given-names></name><name><surname>Mangano</surname><given-names>VD</given-names></name><name><surname>Verra</surname><given-names>F</given-names></name><name><surname>Bancone</surname><given-names>G</given-names></name><name><surname>Nebie</surname><given-names>I</given-names></name><name><surname>Sirima</surname><given-names>BS</given-names></name><name><surname>Liotta</surname><given-names>F</given-names></name><name><surname>Frosali</surname><given-names>F</given-names></name><name><surname>Angeli</surname><given-names>R</given-names></name><name><surname>Severini</surname><given-names>C</given-names></name><name><surname>Sannella</surname><given-names>AR</given-names></name><name><surname>Bonini</surname><given-names>P</given-names></name><name><surname>Lucibello</surname><given-names>M</given-names></name><name><surname>Maggi</surname><given-names>E</given-names></name><name><surname>Garaci</surname><given-names>E</given-names></name><name><surname>Coluzzi</surname><given-names>M</given-names></name><name><surname>Cozzolino</surname><given-names>F</given-names></name><name><surname>Annunziato</surname><given-names>F</given-names></name><name><surname>Romagnani</surname><given-names>S</given-names></name><name><surname>Modiano</surname><given-names>D</given-names></name><article-title>Functional deficit of T regulatory cells in Fulani, an ethnic group with low susceptibility to <italic>Plasmodium falciparum</italic> malaria</article-title><source>Proc Natl Acad Sci USA</source><year>2008</year><volume>105</volume><fpage>646</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1073/pnas.0709969105</pub-id><pub-id pub-id-type="pmid">18174328</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Lokki</surname><given-names>AI</given-names></name><name><surname>Jarvela</surname><given-names>I</given-names></name><name><surname>Israelsson</surname><given-names>E</given-names></name><name><surname>Maiga</surname><given-names>B</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Dolo</surname><given-names>A</given-names></name><name><surname>Doumbo</surname><given-names>OK</given-names></name><name><surname>Meri</surname><given-names>S</given-names></name><name><surname>Holmberg</surname><given-names>V</given-names></name><article-title>Lactase persistence genotypes and malaria susceptibility in Fulani of Mali</article-title><source>Malar J</source><year>2011</year><volume>10</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/1475-2875-10-9</pub-id><pub-id pub-id-type="pmid">21235777</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Tiono</surname><given-names>AB</given-names></name><name><surname>Ouedraogo</surname><given-names>A</given-names></name><name><surname>Ogutu</surname><given-names>B</given-names></name><name><surname>Diarra</surname><given-names>A</given-names></name><name><surname>Coulibaly</surname><given-names>B</given-names></name><name><surname>Gansane</surname><given-names>A</given-names></name><name><surname>Sirima</surname><given-names>SB</given-names></name><name><surname>O&#x02019;Neil</surname><given-names>G</given-names></name><name><surname>Mukhopadhyay</surname><given-names>A</given-names></name><name><surname>Hamed</surname><given-names>K</given-names></name><article-title>A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of <italic>Plasmodium falciparum</italic> in Burkina Faso</article-title><source>Malar J</source><year>2013</year><volume>12</volume><fpage>79</fpage><pub-id pub-id-type="doi">10.1186/1475-2875-12-79</pub-id><pub-id pub-id-type="pmid">23442748</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Modiano</surname><given-names>D</given-names></name><name><surname>Luoni</surname><given-names>G</given-names></name><name><surname>Sirima</surname><given-names>BS</given-names></name><name><surname>Lanfrancotti</surname><given-names>A</given-names></name><name><surname>Petrarca</surname><given-names>V</given-names></name><name><surname>Cruciani</surname><given-names>F</given-names></name><name><surname>Simpore</surname><given-names>J</given-names></name><name><surname>Ciminelli</surname><given-names>BM</given-names></name><name><surname>Foglietta</surname><given-names>E</given-names></name><name><surname>Grisanti</surname><given-names>P</given-names></name><name><surname>Bianco</surname><given-names>I</given-names></name><name><surname>Modiano</surname><given-names>G</given-names></name><name><surname>Coluzzi</surname><given-names>M</given-names></name><article-title>The lower susceptibility to <italic>Plasmodium falciparum</italic> malaria of Fulani of Burkina Faso (west Africa) is associated with low frequencies of classic malaria-resistance genes</article-title><source>Trans R Soc Trop Med Hyg</source><year>2001</year><volume>95</volume><fpage>149</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/S0035-9203(01)90141-5</pub-id><pub-id pub-id-type="pmid">11355545</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Farouk</surname><given-names>SE</given-names></name><name><surname>Dolo</surname><given-names>A</given-names></name><name><surname>Bereczky</surname><given-names>S</given-names></name><name><surname>Kouriba</surname><given-names>B</given-names></name><name><surname>Maiga</surname><given-names>B</given-names></name><name><surname>Farnert</surname><given-names>A</given-names></name><name><surname>Perlmann</surname><given-names>H</given-names></name><name><surname>Hayano</surname><given-names>M</given-names></name><name><surname>Montgomery</surname><given-names>SM</given-names></name><name><surname>Doumbo</surname><given-names>OK</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><article-title>Different antibody- and cytokine-mediated responses to <italic>Plasmodium falciparum</italic> parasite in two sympatric ethnic tribes living in Mali</article-title><source>Microbes Infect</source><year>2005</year><volume>7</volume><fpage>110</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2004.09.012</pub-id><pub-id pub-id-type="pmid">15716067</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Israelsson</surname><given-names>E</given-names></name><name><surname>Vafa</surname><given-names>M</given-names></name><name><surname>Maiga</surname><given-names>B</given-names></name><name><surname>Lysen</surname><given-names>A</given-names></name><name><surname>Iriemenam</surname><given-names>NC</given-names></name><name><surname>Dolo</surname><given-names>A</given-names></name><name><surname>Doumbo</surname><given-names>OK</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Berzins</surname><given-names>K</given-names></name><article-title>Differences in Fcgamma receptor IIa genotypes and IgG subclass pattern of anti-malarial antibodies between sympatric ethnic groups in Mali</article-title><source>Malar J</source><year>2008</year><volume>7</volume><fpage>175</fpage><pub-id pub-id-type="doi">10.1186/1475-2875-7-175</pub-id><pub-id pub-id-type="pmid">18793404</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Nasr</surname><given-names>A</given-names></name><name><surname>Iriemenam</surname><given-names>NC</given-names></name><name><surname>Giha</surname><given-names>HA</given-names></name><name><surname>Balogun</surname><given-names>HA</given-names></name><name><surname>Anders</surname><given-names>RF</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Elghazali</surname><given-names>G</given-names></name><name><surname>Berzins</surname><given-names>K</given-names></name><article-title>FcgammaRIIa (CD32) polymorphism and anti-malarial IgG subclass pattern among Fulani and sympatric ethnic groups living in eastern Sudan</article-title><source>Malar J</source><year>2009</year><volume>8</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.1186/1475-2875-8-43</pub-id><pub-id pub-id-type="pmid">19284648</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Cherif</surname><given-names>MK</given-names></name><name><surname>Sanou</surname><given-names>GS</given-names></name><name><surname>Maiga</surname><given-names>B</given-names></name><name><surname>Israelsson</surname><given-names>E</given-names></name><name><surname>Ouedraogo</surname><given-names>AL</given-names></name><name><surname>Bougouma</surname><given-names>EC</given-names></name><name><surname>Diarra</surname><given-names>A</given-names></name><name><surname>Ouedraogo</surname><given-names>A</given-names></name><name><surname>Ouattara</surname><given-names>AS</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Dolo</surname><given-names>A</given-names></name><name><surname>Cavanagh</surname><given-names>DR</given-names></name><name><surname>Theisen</surname><given-names>M</given-names></name><name><surname>Modiano</surname><given-names>D</given-names></name><name><surname>Sirima</surname><given-names>SB</given-names></name><name><surname>Nebie</surname><given-names>I</given-names></name><article-title>FcgammaRIIa polymorphism and anti-malaria-specific IgG and IgG subclass responses in populations differing in susceptibility to malaria in Burkina Faso</article-title><source>Scand J Immunol</source><year>2012</year><volume>75</volume><fpage>606</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3083.2012.02690.x</pub-id><pub-id pub-id-type="pmid">22268665</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Luoni</surname><given-names>G</given-names></name><name><surname>Verra</surname><given-names>F</given-names></name><name><surname>Arca</surname><given-names>B</given-names></name><name><surname>Sirima</surname><given-names>BS</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Coluzzi</surname><given-names>M</given-names></name><name><surname>Kwiatkowski</surname><given-names>D</given-names></name><name><surname>Modiano</surname><given-names>D</given-names></name><article-title>Antimalarial antibody levels and IL4 polymorphism in the Fulani of West Africa</article-title><source>Genes Immun</source><year>2001</year><volume>2</volume><fpage>411</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1038/sj.gene.6363797</pub-id><pub-id pub-id-type="pmid">11704810</pub-id></mixed-citation></ref></ref-list></back></article>